← FDA DRUG APPROVALS

FDA NDA · NDA021723

LYRICA

Sponsor: CP PHARMS

APPLICATION
NDA021723
TYPE
NDA
ORIGINAL APPROVAL
2004-12-30
LATEST ACTION
2004-12-30
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

LYRICAPrescription
PREGABALIN 300MG · CAPSULE · ORAL
LYRICAPrescription
PREGABALIN 200MG · CAPSULE · ORAL
LYRICAPrescription
PREGABALIN 100MG · CAPSULE · ORAL
LYRICAPrescription
PREGABALIN 50MG · CAPSULE · ORAL
LYRICAPrescription
PREGABALIN 225MG · CAPSULE · ORAL
LYRICAPrescription
PREGABALIN 150MG · CAPSULE · ORAL
LYRICAPrescription
PREGABALIN 75MG · CAPSULE · ORAL
LYRICAPrescription
PREGABALIN 25MG · CAPSULE · ORAL

Approval history

2004-12-30Type 6 - New Indication (no longer used) · Original · standardHealthcare Professional SheetAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →